Affimed

Lady in sunshine

Press Room | Events

Meet representatives of Affimed Therapeutics AG on following conferences:

The 25th International Conference "Advances in the Application of the Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer stem Cells"
Island of Rhodes, Greece, 16 - 18.06.2008

"Alternative antibody formats: fusions and fragments"; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO of Affimed
"Development of a bispecific tetravalent antibody for killing of EpCAM positive cells"; speaker: Dr. Fabrice le Gall, Head of Engineering, Affimed
Bio International Convention 2008, San Diego, USA 17. - 20.06.2008
Gavin D. Clark, Vice President Business Development, Dr. Volker Lang, CBO of Affimed, Dr. Stephan Knackmuss, Head of Sreening, Affimed, Partnering Forum
BioEquity, Amsterdam, Netherlands, 28. - 29.05.2008
Dr Florian Fischer, CFO of Affimed
2. Ernst & Young Life Science Day, Neue Börse Frankfurt/ Main, Germany, 08.05.2008
Dr. Rolf Günther, CEO of Affimed
BFF Biotech & Finance Forum, Stuttgart, Germany, 28.04.2008
Presentation of Dr. Florian Fischer, CFO of Affimed
AACR (American Association for Cancer Research)Annual Meeting 2008, San Diego, USA
12. -16.04.2008

Poster Session, 15. 04.2008 at 1 p.m >Development of a bispecific tetravalent antibody for treating Hodgkin's Disease<; Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed, Dr. Uwe Reusch, Head of Cell Culture, Affimed
Bio Europe Spring, Madrid, Spain, 07. - 09.04.2008
Bio Capital Europe 2008, Amsterdam, Netherlands, 05.03.2008
speaker: Dr Rolf Günther, CEO of Affimed
24th International Conference: "Advances in the Application of Monoclonal Antibodies in Clinical Oncology", Cyprus 16. 06.-20.06.2007
>Recruitment of NK cells for lysing tumor cells<; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed
University of Vienna, Austria, 01.06.2007
>The recruitment of immune effector cells to lyse tumor cells using recombinant antibodies<; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed
BIO 2007 International Convention, Boston, MA, USA, 06.-09.05.2007
www.bio2007.org
BioCapital Europe 2007, Amsterdam, Netherlands, 28.03.2007
speaker: Dr Rolf Günther, CEO of Affimed
www.biocapitaleurope.com
Antibodies in Discovery and Development, London, 28.-29.03.2007
»Increasing efficiency and productivity of technology, research and development of therapeutic antibody candidates«; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed
World Biopharm Forum 2007, Development of new therapies for cancer, New Hall, Cambridge, UK, 19.-21.03.2007
»Exploiting the potential of NK cells to kill tumor cells«; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed
New Binding Proteins Conference, Halle, 01.-03.03.2007
»Recruitment of immune cells to destroy tumor cells using novel antibody products«; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed
Symposium Universitäts-Kinder- und Jugendklinik, Rostock, 23.-24.02.2007
»Rekombinante multivalente Antikörper für den Einsatz in der Onkologie«; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed